NHS will not pay for drugs that offer little clinical benefit, says cancer fund bossBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h125 (Published 08 January 2015) Cite this as: BMJ 2015;350:h125
- Zosia Kmietowicz
- 1The BMJ
The head of the fund that pays for cancer drugs that are not approved for use on the NHS in England has defended the decision to delist some of the drugs it currently finances because they don’t offer patients sufficient clinical benefit.
Peter Clark, chairman of the Cancer Drugs Fund and a practising oncologist, said, “We need to get maximum value for every pound we spend through the CDF [Cancer Drugs Fund]. We can no longer sustain a position where we are funding drugs that don’t offer sufficient clinical benefit when drugs that will do more for patients are coming on stream.”
He was responding to criticism of the Cancer Drugs Fund by two drug companies that have had their drugs removed from the list that the fund will finance. Since …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial